We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

106 hedge funds and large institutions have $80.4M invested in Sanofi Contingent Value Rights in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

6% more capital invested

Capital invested by funds: $76.1M → $80.4M (+$4.28M)

0% more funds holding

Funds holding: 106106 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

Holders
106
Holders Change
Holders Change %
0%
% of All Funds
2.42%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
14
Reduced
19
Closed
9
Calls
$2K
Puts
Net Calls
+$2K
Net Calls Change
-$722K

GCVRZ Hedge Fund Activity: Q3 2018 in Review

106 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2018, worth a combined $80.4M — up 5.6% from $76.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GCVRZ positions and 9 closed out — a net gain of 1 holder — while 14 added to existing stakes and 19 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $448K. The largest seller was Pomelo Capital, exiting entirely with an estimated $683K sold.

  • 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $80.4M of Sanofi Contingent Value Rights stock for Q3 2018, up 5.6% quarter-over-quarter.
  • 10 funds opened new Sanofi Contingent Value Rights positions in Q3 2018 and 9 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q3 2018 was Highbridge Capital Management, an estimated $448K added.
  • The largest Sanofi Contingent Value Rights seller in Q3 2018 was Pomelo Capital, an estimated $683K sold.

Based on aggregated 13F filings for Q3 2018.